MORPHOTEK, INC.

Chlorotoxin polypeptides and conjugates and uses thereof

#2 | 2017-05-04 ✅ Patent 9,868,780 granted on 2018-01-16

US20170121396A1

High affinity antibodies that neutralize enterotoxin B

#3 | 2016-11-17 ✅ Patent 10,023,632 granted on 2018-07-17

US20160333089A1

Antigenic GM-CSF peptides and antibodies to GM-CSF

#4 | 2016-06-02 ✅ Patent 9,637,526 granted on 2017-05-02

US20160152671A1

Chlorotoxin polypeptides and conjugates and uses thereof

#5 | 2016-03-03 ✅ Patent 9,522,195 granted on 2016-12-20

US20160058885A1

Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells

#6 | 2016-01-07 ✅ Patent 9,915,660 granted on 2018-03-13

US20160003829A1

Methods for determining prognosis of colorectal cancer

#7 | 2015-12-31 ✅ Patent 9,603,952 granted on 2017-03-28

US20150374860A1

Treatment of metastatic tumors

#8 | 2015-11-26 ✅ Patent 9,771,429 granted on 2017-09-26

US20150337051A1

TEM-1 diagnostic antibodies

#9 | 2015-05-14 ✅ Patent 9,512,223 granted on 2016-12-06

US20150132291A1

Methods for treatment of gastric cancer

#10 | 2015-03-19 ✅ Patent 9,505,842 granted on 2016-11-29

US20150079104A1

Methods for inhibiting the binding of endosialin to ligands

#11 | 2015-02-19 ✅ Patent 9,359,428 granted on 2016-06-07

US20150050276A1

High affinity antibodies that neutralize enterotoxin B

#12 | 2015-01-29 ✅ Patent 9,234,015 granted on 2016-01-12

US20150030537A1

Chlorotoxin polypeptides and conjugates and uses thereof

#13 | 2014-07-31

US20140212410A1

CO-ADMINISTRATION OF ERIBULIN AND FARLETUZUMAB FOR THE TREATMENT OF BREAST CANCER

#14 | 2014-05-08 ✅ Patent 9,115,197 granted on 2015-08-25

US20140127237A1

Anti-mesothelin antibodies

#15 | 2014-03-27 ✅ Patent 9,422,367 granted on 2016-08-23

US20140086928A1

Antigenic GM-CSF peptides and antibodies to GM-CSF

#16 | 2014-03-13 ✅ Patent 8,895,704 granted on 2014-11-25

US20140072553A1

High affinity antibodies that neutralize enterotoxin B

#17 | 2013-10-31 ✅ Patent 8,956,832 granted on 2015-02-17

US20130287691A1

Cells expressing anti-GD2 antibodies and methods related thereto

#18 | 2013-10-03 ✅ Patent 9,139,656 granted on 2015-09-22

US20130260393A1

TEM-1 diagnostic antibodies

#19 | 2013-07-25 ✅ Patent 9,650,440 granted on 2017-05-16

US20130189272A1

Monoclonal antibodies that specifically block biological activity of a tumor antigen

#20 | 2013-07-18 ✅ Patent 8,889,846 granted on 2014-11-18

US20130183314A1

High affinity antibodies that neutralize enterotoxin B

#21 | 2013-07-11 ✅ Patent 8,658,173 granted on 2014-02-25

US20130177571A1

Anti-mesothelin antibodies

#22 | 2013-03-28 ✅ Patent 8,524,237 granted on 2013-09-03

US20130078242A1

Antibodies with immune effector activity and that internalize in endosialin-positive cells

#23 | 2013-03-07 ✅ Patent 8,623,364 granted on 2014-01-07

US20130058945A1

Antigenic GM-CSF peptides and antibodies to GM-CSF

#24 | 2013-02-21 ✅ Patent 9,023,595 granted on 2015-05-05

US20130045163A1

Treatment of metastatic tumors

#25 | 2013-01-31 ✅ Patent 9,018,347 granted on 2015-04-28

US20130028836A1

Chlorotoxin polypeptides and conjugates and uses thereof

#26 | 2012-12-27 ✅ Patent 8,507,657 granted on 2013-08-13

US20120328524A1

Anti-GD2 antibodies

#27 | 2012-09-20 ✅ Patent 8,481,703 granted on 2013-07-09

US20120237509A1

Anti-mesothelin antibodies

#28 | 2012-08-16

US20120207771A1

FOLATE RECEPTOR ALPHA AS A DIAGNOSTIC AND PROGNOSTIC MARKER FOR FOLATE RECEPTOR ALPHA-EXPRESSING CANCERS

#29 | 2012-07-05 ✅ Patent 8,236,932 granted on 2012-08-07

US20120171223A1

High affinity antibodies that neutralize enterotoxin B

#30 | 2012-07-05 ✅ Patent 9,144,614 granted on 2015-09-29

US20120171200A1

Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells

#31 | 2012-06-28

US20120164137A1

ANTI-FOLATE RECEPTOR ALPHA ANTIBODY GLYCOFORMS

#32 | 2012-06-21

US20120156131A1

DIAGNOSIS AND TREATMENT OF TUMORS

#33 | 2011-12-22

US20110311445A1

DIAGNOSIS AND TREATMENT OF MYELOID AND LYMPHOID CELL CANCERS

#34 | 2011-02-10 ✅ Patent 8,895,000 granted on 2014-11-25

US20110033455A1

Methods for inhibiting the binding of endosialin to ligands

#35 | 2011-02-03 ✅ Patent 8,470,607 granted on 2013-06-25

US20110027177A1

Inhibition of angiogenesis

#36 | 2010-12-09 ✅ Patent 8,445,229 granted on 2013-05-21

US20100311169A1

Methods of generating high-production of antibodies from hybridomas created by in vitro immunization

#37 | 2010-10-28 ✅ Patent 8,318,168 granted on 2012-11-27

US20100272730A1

Antigenic GM-CSF peptides and antibodies to GM-CSF

#38 | 2010-10-14

US20100260769A1

ENDOSIALIN BINDING MOLECULES

#39 | 2010-07-13 ✅ Patent 7,754,450 granted on 2010-07-13

US10714228

Methods of generating high-production of antibodies from hybridomas created by in vitro immunization

#40 | 2010-02-04 ✅ Patent 8,206,710 granted on 2012-06-26

US20100028336A1

Anti-mesothelin antibodies

#41 | 2010-01-28

US20100021996A1

Genetically Altered Anti-body Producing Cell Lines With Improved Antibody Characteristics

#42 | 2010-01-28 ✅ Patent 8,389,691 granted on 2013-03-05

US20100021454A1

Antibodies with immune effector activity and that internalize in endosialin-positive cells

#43 | 2010-01-14 ✅ Patent 8,278,065 granted on 2012-10-02

US20100008851A1

Polynucleotides encoding anti-GD2 antibodies

#44 | 2009-12-31 ✅ Patent 8,124,083 granted on 2012-02-28

US20090324594A1

Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells

#45 | 2009-12-29 ✅ Patent 7,638,334 granted on 2009-12-29

US10348074

Method for generating engineered cells by homologously recombining segments having increased degeneracy

#46 | 2009-12-10 ✅ Patent 8,227,439 granted on 2012-07-24

US20090304592A1

Treatment of metastatic tumors

#47 | 2009-11-05 ✅ Patent 9,624,297 granted on 2017-04-18

US20090274697A1

Monoclonal antibodies that specifically block biological activity of a tumor antigen

#48 | 2009-04-23 ✅ Patent 7,807,416 granted on 2010-10-05

US20090104646A1

Antibodies and methods for generating genetically altered antibodies with enhanced effector function

#49 | 2008-11-27 ✅ Patent 7,741,450 granted on 2010-06-22

US20080292641A1

Antibodies to GM-CSF

#50 | 2008-10-09 ✅ Patent 7,807,382 granted on 2010-10-05

US20080248034A1

Methods for inhibiting the binding of endosialin to ligands

#51 | 2008-07-31 ✅ Patent 7,939,324 granted on 2011-05-10

US20080182242A1

Methods for isolating novel antimicrobial agents from hypermutable mammalian cells

#52 | 2008-07-24 ✅ Patent 7,759,121 granted on 2010-07-20

US20080176329A1

Methods for generating hypermutable yeast

#53 | 2008-06-05

US20080131427A1

Whole Genome Evolution Technology Applied To Improve Protein And Antibody Yields By Cells

#54 | 2008-05-29

US20080124744A1

Antibodies That Specifically Bind PMS2

#55 | 2007-10-18 ✅ Patent 7,671,179 granted on 2010-03-02

US20070244302A1

Antibodies and methods for generating genetically altered antibodies with high affinity

#56 | 2007-06-26 ✅ Patent 7,235,643 granted on 2007-06-26

US10243130

Antibodies and methods for generating genetically altered antibodies with high affinity

#57 | 2006-10-26 ✅ Patent 7,615,372 granted on 2009-11-10

US20060239911A1

Antibodies with immune effector activity and that internalize in endosialin-positive cells

#58 | 2006-09-14 ✅ Patent 7,592,426 granted on 2009-09-22

US20060204506A1

Anti-mesothelin antibodies

#59 | 2006-03-30 ✅ Patent 7,223,598 granted on 2007-05-29

US20060068497A1

Methods for isolating novel antimicrobial agents from hypermutable mammalian cells

#60 | 2006-01-26 ✅ Patent 8,105,836 granted on 2012-01-31

US20060019383A1

Chemical inhibitors of mismatch repair

#61 | 2006-01-12 ✅ Patent 7,332,584 granted on 2008-02-19

US20060009621A1

Antibodies that specifically bind PMS2

#62 | 2006-01-03 ✅ Patent 6,982,169 granted on 2006-01-03

US9760285

Chemical inhibitors of mismatch repair

#63 | 2005-12-08 ✅ Patent 7,514,216 granted on 2009-04-07

US20050272140A1

Methods for generating hypermutable yeast

#64 | 2005-10-20

US20050232919A1

Monoclonal antibodies that specifically block biological activity of a tumor antigen

#65 | 2005-03-03 ✅ Patent 7,604,994 granted on 2009-10-20

US20050048621A1